ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0701

miRNome Sequencing Identifies a Unique Profile of Circulating MicroRNAs in Early Knee Osteoarthritis
Abstract Number: 1009

Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
Abstract Number: 0957

Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis
Abstract Number: 1106

MMP Mediated Type I Collagen Degradation Is Associated with Erosive Hand Osteoarthritis in a Hospital-based Observational Cohort – the NOR-HAND Study
Abstract Number: 0613

Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Abstract Number: 0772

Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Abstract Number: 0463

Molecular Diagnosis of Childhood Immunodysregulation, Endocrinopathy and Enteropathy X-linked (IPEX)-Like Syndrome and Implications for Clinical Management
Abstract Number: 0036

Molecular Phenotyping of Late-Stage Knee Osteoarthritis Synovium Through Total RNA-Sequencing
Abstract Number: 0453

Monitoring of BK Reactivation and Long-term Safety on JAK1/2 Inhibition with Baricitinib
Abstract Number: 1325

Monoclonal Gammopathy in Psoriatic Arthritis
Abstract Number: 0729

Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up
Abstract Number: 0151

More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
Abstract Number: 0981

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic Status: The California Lupus Surveillance Project, 2007-2017
Abstract Number: 0854

Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events
Abstract Number: 0582

Mortality and Cost of Hospitalization: Do Hospitals Caring for More SLE Patients Perform Better?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].